Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bryostatin 1 - Synaptogenix

Next Previous
Drug Profile

Bryostatin 1 - Synaptogenix

Alternative Names: Bryostatin-1 - Neurotrope; MW-904

Latest Information Update: 02 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience
  • Developer Blanchette Rockefeller Neurosciences Institute; National Cancer Institute (USA); National Institute on Aging; Rettsyndrome.org; Synaptogenix
  • Class Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Behavioural disorder therapies; Macrocyclic compounds; Small molecules; Vascular disorder therapies
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Multiple sclerosis
  • Preclinical Pervasive child development disorders
  • No development reported Depressive disorders; Fragile X syndrome; Niemann-Pick disease type C; Parkinson's disease; Rett syndrome; Stroke; Traumatic brain injuries

Most Recent Events

  • 27 Jun 2024 US FDA approves IND application for Bryostatin-1 in Multiple sclerosis
  • 11 Apr 2024 Phase-I clinical trials in Multiple sclerosis in USA (IV) (NCT06190912)
  • 19 Dec 2023 Updated efficacy data from a phase IIb trial in Alzheimer's disease released by Synaptogenix

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top